MA30163B1 - Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques - Google Patents
Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiquesInfo
- Publication number
- MA30163B1 MA30163B1 MA31117A MA31117A MA30163B1 MA 30163 B1 MA30163 B1 MA 30163B1 MA 31117 A MA31117 A MA 31117A MA 31117 A MA31117 A MA 31117A MA 30163 B1 MA30163 B1 MA 30163B1
- Authority
- MA
- Morocco
- Prior art keywords
- amyloid
- disorders
- amyloidosis
- diseases
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
Abstract
La présente invention concerne des procédés et des compositions d'utilisation thérapeutique et diagnostique dans le traitement de maladies et de troubles causés par des protéines amyloïde ou de type amyloïde ou associés à ces protéines, notamment l'amylose, un groupe de troubles et d'anomalies associés à la protéine amyloïde tels que la maladie d'Alzheimer. Cette invention concerne de nouveaux procédés et de nouvelles compositions comprenant des anticorps hautement spécifiques et hautement efficaces qui ont la capacité de reconnaître et de se lier spécifiquement à des épitopes spécifiques d'une gamme de protéines bêta-amyloïde. Les anticorps validés par les enseignements de cette invention conviennent particulièrement au traitement de maladies et de troubles causés par des protéines amyloïdes ou de type amyloïde ou associés à ces protéines notamment l'amylose, un groupe de maladies et de troubles associés à la formation de plaque d'amyloïdes notamment l'amylose secondaire et l'amylose liée à l'âge, notamment des troubles neurologiques tels que la maladie d'Alzheimer (AD).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05027092 | 2005-12-12 | ||
EP06014729 | 2006-07-14 | ||
EP06020766 | 2006-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30163B1 true MA30163B1 (fr) | 2009-01-02 |
Family
ID=37896141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31117A MA30163B1 (fr) | 2005-12-12 | 2008-07-11 | Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques |
Country Status (32)
Country | Link |
---|---|
US (5) | US7772375B2 (fr) |
EP (3) | EP2808032B1 (fr) |
JP (5) | JP5419131B2 (fr) |
KR (4) | KR101591206B1 (fr) |
AR (1) | AR058326A1 (fr) |
AU (1) | AU2006326284B2 (fr) |
BR (1) | BRPI0619748B8 (fr) |
CA (1) | CA2632822C (fr) |
CL (1) | CL2011000010A1 (fr) |
CR (3) | CR9995A (fr) |
CY (1) | CY1115014T1 (fr) |
DK (1) | DK2361638T3 (fr) |
EC (1) | ECSP088530A (fr) |
ES (1) | ES2454253T3 (fr) |
HK (2) | HK1161141A1 (fr) |
HR (2) | HRP20140251T1 (fr) |
IL (6) | IL191230A (fr) |
MA (1) | MA30163B1 (fr) |
MX (2) | MX2008007477A (fr) |
MY (1) | MY167887A (fr) |
NO (1) | NO345996B1 (fr) |
NZ (1) | NZ568012A (fr) |
PH (1) | PH12011502389A1 (fr) |
PL (1) | PL2361638T3 (fr) |
PT (1) | PT2361638E (fr) |
RS (1) | RS53291B (fr) |
RU (2) | RU2551782C2 (fr) |
SG (1) | SG10201404801YA (fr) |
SI (1) | SI2361638T1 (fr) |
TW (2) | TWI579303B (fr) |
WO (1) | WO2007068412A2 (fr) |
ZA (1) | ZA200804916B (fr) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
WO2004092197A2 (fr) * | 2003-04-07 | 2004-10-28 | The Regents Of The University Of California | Peptides specifiques de l'amyloide et leurs utilisations |
PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
RU2551782C2 (ru) | 2005-12-12 | 2015-05-27 | Ац Иммуне Са | Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами |
KR101152557B1 (ko) | 2005-12-12 | 2012-09-07 | 에이씨 이뮨 에스.에이. | 치료 백신 |
US7959949B2 (en) | 2006-04-27 | 2011-06-14 | University Of Central Florida Research Foundation, Inc. | Functionalized nanoceria composition for ophthalmic treatment |
WO2008011348A2 (fr) * | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Anticorps humanisé |
KR20190003862A (ko) * | 2006-07-14 | 2019-01-09 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
EP3988566A1 (fr) * | 2006-07-14 | 2022-04-27 | AC Immune SA | Anticorps humanisés contre le peptide amyloïde-bêta |
KR20150002879A (ko) * | 2006-10-02 | 2015-01-07 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
CA2670418A1 (fr) | 2006-11-24 | 2008-05-29 | Ac Immune Sa | Nouveaux composes destines au traitement de maladies associes a des proteines amyloides ou de type amyloide |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
CA2764852C (fr) | 2007-01-05 | 2018-09-18 | University Of Zurich | Procede pour fournir des molecules de liaison et des cibles specifiques a une maladie. |
US7939075B2 (en) | 2007-01-11 | 2011-05-10 | Philipps-Universitaet Marburg | Human monoclonal anti-amyloid-beta antibodies |
EP2486928A1 (fr) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Procédé pour le traitement des amyloses |
MX2009009234A (es) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | Uso nuevo de inhibidores de ciclasa de glutaminilo. |
US20090022728A1 (en) * | 2007-03-09 | 2009-01-22 | Rinat Neuroscience Corporation | Methods of treating ophthalmic diseases |
EP2865670B1 (fr) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
EP2152309B1 (fr) | 2007-05-14 | 2013-07-10 | Medtronic, Inc. | Procédés et dispositif permettant de neutraliser des agents solubles toxiques dans le cerveau |
US8323654B2 (en) * | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
TW201518320A (zh) * | 2007-06-12 | 2015-05-16 | Ac Immune Sa | 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途 |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US9119391B1 (en) | 2007-07-16 | 2015-09-01 | University Of Central Florida Research Foundation, Inc. | Polymer coated ceria nanoparticles for selective cytoprotection |
CN105169388A (zh) * | 2007-10-05 | 2015-12-23 | 基因技术公司 | 人源化抗体 |
AU2015200604B2 (en) * | 2007-10-05 | 2016-10-27 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
EP2586795B1 (fr) | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Utilisation d'anticorps anti-beta amyloide aux maladies oculaires |
EP2205632B1 (fr) * | 2007-10-05 | 2016-11-16 | Genentech, Inc. | Utilisation d'anticorps anti-beta amyloide aux maladies oculaires |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
JPWO2009104736A1 (ja) * | 2008-02-22 | 2011-06-23 | 田平 武 | 組織アミロイドプラーク親和性抗体及びそれを用いた医薬組成物 |
EP2288258A4 (fr) * | 2008-04-25 | 2012-10-31 | Univ Oklahoma | Inhibition de la néovascularisation par des nanoparticules d'oxyde de cérium |
US8916199B1 (en) | 2008-04-25 | 2014-12-23 | University of Central Florida Research Foundation, Ind. | Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide |
AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
CA2730073A1 (fr) * | 2008-07-09 | 2010-01-14 | University Of Zurich | Procede d'activation de la neurogenese |
US9127202B1 (en) | 2008-07-18 | 2015-09-08 | University Of Central Florida Research Foundation, Inc. | Biocompatible nano rare earth oxide upconverters for imaging and therapeutics |
MX2011000875A (es) | 2008-07-21 | 2011-04-05 | Probiodrug Ag | Ensayo de anticuerpo de diagnostico. |
EP2149380A1 (fr) * | 2008-07-29 | 2010-02-03 | Medivet Pharma, S.L. | Compositions d'immunothérapie vétérinaire pour le disfonctionnement cognitif associé à l'âge |
SI2370466T1 (sl) | 2008-12-19 | 2015-11-30 | Biogen International Neuroscience Gmbh | Človeška avtoprotitelesa proti alfa-sinukleinu |
US8883519B1 (en) | 2009-03-17 | 2014-11-11 | University Of Central Florida Research Foundation, Inc. | Oxidase activity of polymeric coated cerium oxide nanoparticles |
US9585840B1 (en) | 2009-07-10 | 2017-03-07 | University Of Central Florida Research Foundation, Inc. | Redox active cerium oxide nanoparticles and associated methods |
ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
US8795731B1 (en) | 2009-10-12 | 2014-08-05 | University Of Central Florida Research Foundation, Inc. | Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation |
EP2311823A1 (fr) | 2009-10-15 | 2011-04-20 | AC Immune S.A. | Composés de 2,6-diaminopyridine appropriés pour le traitement de maladies liées à des protéines amyloïdes ou pour le traitement de maladies oculaires |
CN102051407B (zh) * | 2009-11-09 | 2012-12-12 | 中国医学科学院医药生物技术研究所 | Hiv-1前体蛋白早成熟化诱导剂的筛选方法 |
CN102781962B (zh) | 2010-03-03 | 2014-12-10 | 阿布林克斯公司 | 双互补位A-β结合多肽 |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
CA2796339C (fr) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Proteines de liaison a la beta amyloide |
US20110256064A1 (en) | 2010-04-16 | 2011-10-20 | Ac Immune, S.A. | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins |
NZ602777A (en) | 2010-04-16 | 2014-07-25 | Ac Immune Sa | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
EP2560953B1 (fr) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibiteurs de glutaminyl cyclase |
CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
US9289488B2 (en) | 2010-08-12 | 2016-03-22 | Ac Immune Sa | Vaccine engineering |
CA2808187A1 (fr) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Proteines de liaison beta-amyloides |
US8877207B2 (en) | 2010-09-17 | 2014-11-04 | University Of Central Florida Research Foundation, Inc. | Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of Alzheimer's disease and associated methods |
WO2012055933A1 (fr) | 2010-10-26 | 2012-05-03 | Ac Immune S.A. | Préparation d'un produit de recombinaison antigénique |
EP3208282A1 (fr) | 2010-11-30 | 2017-08-23 | F. Hoffmann-La Roche AG | Anticorps de récepteur de barrière hémato-encéphalique de basse affinité et leurs utilisations |
EP2670434B1 (fr) | 2011-01-31 | 2018-12-26 | Tau Bio-Logic Corp. | Traitement de tauopathies |
AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
US8951539B1 (en) | 2011-06-07 | 2015-02-10 | University Of Central Florida Research Foundation, Inc. | Methods of promoting angiogenesis using cerium oxide nanoparticles |
DK2723379T3 (en) | 2011-06-23 | 2018-10-15 | Biogen Int Neuroscience Gmbh | ANTI-ALPHA SYNUCLEIN BINDING MOLECULES |
US9161950B2 (en) | 2011-09-21 | 2015-10-20 | University Of Central Florida Foundation, Inc. | Neuronal protection by cerium oxide nanoparticles |
PT2579042E (pt) * | 2011-10-04 | 2014-09-09 | Affiris Ag | Método para detecção de anticorpos específicos para a numa amostra biológica. |
WO2013059322A2 (fr) * | 2011-10-17 | 2013-04-25 | Lawrence Steinman | Peptide bêta-amyloïde utilisé à des fins thérapeutiques pour lutter contre l'inflammation |
MX362175B (es) * | 2011-11-29 | 2019-01-07 | Proclara Biosciences Inc | Composiciones de proteina del gen 3 de bacteriofago y sus usos como agentes de union amiloides. |
KR102115438B1 (ko) | 2012-05-21 | 2020-05-27 | 제넨테크, 인크. | 혈액-뇌 장벽 수송의 안전성을 개선하는 방법 |
CN105579061A (zh) * | 2012-07-03 | 2016-05-11 | 杨森阿尔茨海默氏症免疫治疗公司 | C端和中央表位的Aβ抗体 |
WO2014056816A1 (fr) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | Association d'un anticorps aβ et d'un inhibiteur de bace |
EP3563849A3 (fr) * | 2012-10-25 | 2020-02-12 | The General Hospital Corporation | Polythérapies pour le traitement de la maladie d'alzheimer et des troubles associés |
US9463437B2 (en) | 2013-02-14 | 2016-10-11 | University Of Central Florida Research Foundation, Inc. | Methods for scavenging nitric oxide using cerium oxide nanoparticles |
JP6490574B2 (ja) * | 2013-02-28 | 2019-03-27 | 国立研究開発法人国立がん研究センター | 不溶性フィブリンに対する抗体 |
SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
SG11201601823TA (en) | 2013-09-13 | 2016-04-28 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
TWI705824B (zh) * | 2014-02-08 | 2020-10-01 | 美商建南德克公司 | 治療阿茲海默症之方法 |
CN107001473B (zh) | 2014-11-19 | 2021-07-09 | 豪夫迈·罗氏有限公司 | 抗-运铁蛋白受体抗体及使用方法 |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
TN2017000543A1 (en) | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
US10870709B2 (en) | 2016-07-22 | 2020-12-22 | New York University | Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides |
US10385096B2 (en) * | 2016-08-30 | 2019-08-20 | Council Of Scientific & Industrial Research | Pro-Amb reverse turn restricted bioactive peptide analogues |
US11397188B2 (en) * | 2017-03-30 | 2022-07-26 | Board Of Regents, The University Of Texas System | Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease |
CA3073066A1 (fr) | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | Compositions pharmaceutiques contenant des anticorps anti-beta-amyloides |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
JP7210612B2 (ja) * | 2018-05-30 | 2023-01-23 | ナショナル ヘルス リサーチ インスティチューツ | 抗aベータ抗体及びその使用 |
US11155609B2 (en) | 2019-04-05 | 2021-10-26 | TauC3 Biologies Limited | Anti-TAUC3 antibodies and uses thereof |
US20230027014A1 (en) * | 2019-11-12 | 2023-01-26 | Ambetex Pty Ltd | Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
CN113057963B (zh) * | 2021-03-31 | 2022-05-20 | 华中科技大学 | 一种用于清除β-淀粉样蛋白的特异性捕获载体及其应用 |
WO2022251048A1 (fr) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anticorps anti-amyloïde bêta et leurs utilisations |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
US5231170A (en) | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
US5525339A (en) | 1986-08-27 | 1996-06-11 | Dms Pharmaceutical Inc. | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
DE3702789A1 (de) | 1987-01-30 | 1988-08-18 | Bayer Ag | Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins |
CA1340802C (fr) | 1987-08-15 | 1999-10-26 | Yasuyuki Takahashi | Proteine precurseur de l'amyloide senile et anticorps specifique pour cette proteine |
US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
US6287793B1 (en) | 1988-08-19 | 2001-09-11 | Elan Pharmaceuticals, Inc. | Diagnostic methods for alzheimer's disease |
US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5262332A (en) | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
US5234814A (en) | 1989-06-01 | 1993-08-10 | Du Pont Merck Pharmaceutical Company | Diagnostic assay for alzheimer's disease |
US5705401A (en) | 1991-11-12 | 1998-01-06 | The University Of Melbourne | Method of assaying for alzheimer's disease |
US5811517A (en) * | 1992-01-27 | 1998-09-22 | Icos Corporation | ICAM-related protein variants |
US20010029293A1 (en) | 1992-01-27 | 2001-10-11 | Icos Corporation | Icam-related protein |
US5538845A (en) | 1992-02-05 | 1996-07-23 | Athena Neurosciences, Inc. | Beta-amyloid peptide production inhibitors and methods for their identification |
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
US5837672A (en) | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US5605811A (en) | 1992-10-26 | 1997-02-25 | Athena Neurosciences, Inc. | Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein |
US5891623A (en) | 1992-11-09 | 1999-04-06 | Consorzio Per Le Biotecnologie | Diagnosis and treatment of AIDS onset |
ZA938243B (en) | 1992-11-12 | 1995-05-04 | Hybritech Inc | Altered affinity polypeptides of metal chelate binding antibodies |
US5955317A (en) | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
EP0683234B2 (fr) | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation |
CA2115900A1 (fr) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Cribles pharmaceutiques et anticorps |
EP0729976A1 (fr) * | 1993-11-19 | 1996-09-04 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre des cellules medulloblastomateuses humaines |
CA2127476C (fr) | 1994-07-06 | 1999-12-07 | Daniel G. Pomerleau | Bucheronnage ou mesurage en utilisant la trebucheuse |
US5626332A (en) * | 1994-07-29 | 1997-05-06 | Harris Corporation | Vibration isolation system using plural signals for control |
BR9509421A (pt) | 1994-10-21 | 1997-09-30 | Innogenetics Nv | Novas sequências de genotipos de vírus de hepatite C e uso como agentes profiláticos terapêuticos e diagnósticos |
US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
CA2214247C (fr) | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulateurs de l'agregation de substances amyloides |
AU6255096A (en) * | 1995-06-07 | 1996-12-30 | Mount Sinai School Of Medicine Of The City University Of New York, The | Pegylated modified proteins |
JPH09178743A (ja) | 1995-12-27 | 1997-07-11 | Oriental Yeast Co Ltd | 可溶性appの定量法 |
US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
US20020086847A1 (en) | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
IT1293511B1 (it) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
AU9454098A (en) * | 1997-09-24 | 1999-04-12 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6998124B1 (en) * | 1999-04-14 | 2006-02-14 | Smithkline Beecham Corporation | Erythropoietin receptor antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
DK1409654T3 (da) | 1999-06-16 | 2008-12-08 | Boston Biomedical Res Inst | Immunologisk styring af beta-amyloid-niveauer in vivo |
IL142948A0 (en) * | 1999-09-03 | 2002-04-21 | Univ Ramot | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
US6294171B2 (en) | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
US20020094335A1 (en) | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
US20020182660A1 (en) | 2000-02-18 | 2002-12-05 | Fong Kei-Lai L. | N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43) |
IL151378A0 (en) * | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
EP1130032A1 (fr) | 2000-02-28 | 2001-09-05 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Anticorps monochaines reconnaissant le récepteur humain de type 2 du facteur de croissance vasculaire endothéliale (VEGFR-2/KDR) |
AU2001253020A1 (en) | 2000-03-30 | 2001-10-15 | Elan Pharmaceuticals, Inc. | Screening markers and methods for neurodegenerative disorders |
US7371365B2 (en) | 2000-04-04 | 2008-05-13 | Mayo Foundation For Medical Education And Research | Methods for detecting parenchymal plaques in vivo |
US20020009445A1 (en) | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
US7067133B2 (en) | 2000-09-06 | 2006-06-27 | Aventis Pharma S.A. | Methods and compositions for diseases associated with amyloidosis |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
US20040191264A1 (en) | 2001-02-19 | 2004-09-30 | Nielsen Klaus Gregorius | Synthetic vaccine agents |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
ES2437875T3 (es) | 2001-04-30 | 2014-01-14 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el péptido beta-amiloide |
ES2312569T3 (es) | 2001-04-30 | 2009-03-01 | Eli Lilly And Company | Anticuerpos humanizados. |
ES2228697T3 (es) | 2001-06-12 | 2005-04-16 | Wiltfang, Jens | Anticuerpo monoclonal, mab 1e8, que es especifico para los dos primeros aminoacidos de peptidos beta-amiloides y su utilizacion en la deteccion de peptidos beta-amiloides y/o sapp alfa. |
US6638722B2 (en) * | 2001-06-13 | 2003-10-28 | Invitrogen Corporation | Method for rapid amplification of DNA |
US20020197258A1 (en) | 2001-06-22 | 2002-12-26 | Ghanbari Hossein A. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
CN1396183A (zh) | 2001-07-13 | 2003-02-12 | 张小如 | 降低脑内与老年痴呆有关的淀粉样变纤维的融合人抗体 |
WO2003014162A1 (fr) | 2001-08-03 | 2003-02-20 | Medical & Biological Laboratories Co., Ltd. | Anticorps reconnaissant la proteine beta-amyloide liee au ganglioside gm1, et adn codant l'anticorps |
AU2002329775C1 (en) | 2001-08-17 | 2011-04-07 | Eli Lilly And Company | Assay method for alzheimer's disease |
EP1519740A4 (fr) | 2001-08-17 | 2005-11-09 | Lilly Co Eli | Amelioration rapide des processus cognitifs dans les etats pathologiques lies a l'a-beta |
US20040192898A1 (en) | 2001-08-17 | 2004-09-30 | Jia Audrey Yunhua | Anti-abeta antibodies |
JP2005500389A (ja) | 2001-08-17 | 2005-01-06 | イーライ・リリー・アンド・カンパニー | Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用 |
US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
EP1448601A4 (fr) * | 2001-11-02 | 2006-04-26 | Diagenics Internat Corp | Methodes et compositions d'anticorps monoclonaux specifiques des proteines beta-amyloides |
EP1975179A1 (fr) | 2001-12-26 | 2008-10-01 | Araclon Biotech, S.L. | Anticorps polyclonaux, leur procédé de préparation et leur utilisation |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US20030190689A1 (en) | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
EP1497321B1 (fr) | 2002-04-19 | 2011-06-29 | The Governing Council Of The University Of Toronto | Methodes et compositions immunologiques pour le traitement de la maladie d'alzheimer |
ATE419871T1 (de) | 2002-04-25 | 2009-01-15 | Lilly Co Eli | Verfahren zur behandlung von angststörungen bei älteren personen |
EP1523499A2 (fr) | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments du peptide beta-amyloide en tant que cibles pour la vaccination contre la maladie d'alzheimer |
JP2006516535A (ja) | 2002-09-12 | 2006-07-06 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア | 異なる配列のタンパク質から形成されたアミロイドに共通する高分子量凝集中間体に対して特異的な免疫原および対応する抗体 |
WO2004029629A1 (fr) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | Anticorps monoclonaux beta-amyloide n-11 tronques, compositions, methodes et utilisations |
US20070213512A1 (en) | 2002-10-01 | 2007-09-13 | Krafft Grant A | Amyloid beta peptide analogs and assemblies thereof |
CA2501945A1 (fr) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methodes de traitement de la maladie d'alzheimer au moyen d'anticorps diriges contre le peptide beta-amyloide et compositions les comprenant |
DE10256900A1 (de) * | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
US20070010435A1 (en) | 2002-12-19 | 2007-01-11 | New York University | Method for treating amyloid disease |
EP1439192A1 (fr) * | 2003-01-15 | 2004-07-21 | Xerion Pharmaceuticals AG | Inhibiteurs de neuropilin-1 |
US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US20060135403A1 (en) | 2002-12-24 | 2006-06-22 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
AT413945B (de) | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
JP2006516639A (ja) | 2003-02-01 | 2006-07-06 | ニユーララブ・リミテツド | 可溶性A−βに対する抗体を生成させるための能動免疫 |
EP1596809B1 (fr) * | 2003-02-10 | 2010-05-26 | Applied Molecular Evolution, Inc. | Molecules de liaison au peptide abeta |
US20040242845A1 (en) | 2003-02-21 | 2004-12-02 | Nicolau Yves Claude | Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them |
WO2005028511A2 (fr) | 2003-03-28 | 2005-03-31 | Centocor, Inc. | Anticorps anti-amyloides, compositions, procedes et utilisations |
EP1469312A1 (fr) | 2003-04-18 | 2004-10-20 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Le diagnostic de la maladie d'Alzheimer |
US20040223912A1 (en) | 2003-05-07 | 2004-11-11 | Montalto Michael Christopher | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
ES2246178B1 (es) | 2003-05-08 | 2007-03-01 | Universidad De Zaragoza. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
EP1480041A1 (fr) | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Méthode de prédiction, diagnostic et diagnostic différential de la maladie d'Alzheimer |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
WO2005011599A2 (fr) | 2003-08-01 | 2005-02-10 | Northwestern University | Anticorps specifiques des oligomeres a proteines beta amyloides toxiques |
EP1666061A1 (fr) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Utilisation d'un anticorps |
CA2538076A1 (fr) | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Anticorps monoclonaux specifiques a des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides formes a partir de proteines de sequence differente |
WO2005037209A2 (fr) | 2003-10-14 | 2005-04-28 | University Of South Florida | Procede pour separer un anticorps anti amyloide beta avec un peptide amyloide beta |
JP4870348B2 (ja) | 2003-12-04 | 2012-02-08 | 株式会社ペルセウスプロテオミクス | 細胞表面抗原に対する抗体取得とその抗原同定 |
EP1717250A4 (fr) | 2004-02-20 | 2008-10-01 | Immuno Biological Lab Co Ltd | Anticorps monoclonal et utilisation de celui-ci |
WO2005082939A2 (fr) | 2004-02-23 | 2005-09-09 | Eli Lilly And Company | Anticorps anti-a$g(b) |
JPWO2005105998A1 (ja) | 2004-04-27 | 2008-07-31 | 財団法人化学及血清療法研究所 | ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
CA2572602A1 (fr) | 2004-07-02 | 2006-02-09 | Northwestern University | Anticorps monoclonaux ciblant des ensembles pathologiques d'amyloides .beta. (abeta) |
US20090156471A1 (en) | 2004-07-15 | 2009-06-18 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
KR20070040824A (ko) | 2004-07-30 | 2007-04-17 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법 |
US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
WO2006039470A2 (fr) | 2004-09-29 | 2006-04-13 | Centocor, Inc. | Anticorps anti- amyloide, compositions, techniques et utilisations |
BRPI0518151A2 (pt) | 2004-10-13 | 2009-06-16 | Ablynx Nv | polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo |
AU2005306997B2 (en) | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
WO2006047670A2 (fr) | 2004-10-26 | 2006-05-04 | Wyeth | Procedes permettant d'evaluer les anticorps diriges contre des antigenes associes aux maladies neurodegeneratives |
EP1813947A4 (fr) | 2004-10-28 | 2008-06-11 | Sanko Junyaku Kk | Procédé d'examen de la maladie d'alzheimer et réactif de diagnostic |
PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
WO2006066049A2 (fr) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Anticorps humanises reconnaissant le peptide beta amyloide |
JP2008524247A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのアミロイドβ抗体 |
WO2006069081A2 (fr) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | Utilisation d'anticorps anti-a$g(b) pour le traitement d'un traumatisme cerebral |
WO2006081171A1 (fr) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Anticorps anti-amyloide humanise |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
DE602006012459D1 (de) | 2005-03-05 | 2010-04-08 | Abbott Gmbh & Co Kg | Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a-beta-oligomere und verfahren zur herstellung dieser antikörper |
ES2259270B1 (es) | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
AU2006259298B2 (en) | 2005-06-17 | 2012-06-14 | Wyeth Llc | Methods of purifying Fc region containing proteins |
JP2007077103A (ja) | 2005-09-16 | 2007-03-29 | Yokohama City Univ | アルツハイマー病の予防又は治療剤 |
CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
PL1976877T5 (pl) * | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
WO2007064917A2 (fr) | 2005-11-30 | 2007-06-07 | Abbott Laboratories | Procedes de preparation de formes recombinees de la proteine beta-amyloide humaine et utilisation desdites proteines |
RU2551782C2 (ru) | 2005-12-12 | 2015-05-27 | Ац Иммуне Са | Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами |
US7427342B2 (en) | 2006-06-02 | 2008-09-23 | General Electric Company | Method and apparatus for shifting current distribution in electrodeionization systems |
WO2008008463A2 (fr) | 2006-07-14 | 2008-01-17 | Trustees Of Columbia University In The City Of New York | PROCÉDÉS ET COMPOSITIONS SERVANT À DÉTECTER ET QUANTIFIER sAPPβ |
WO2008011348A2 (fr) * | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Anticorps humanisé |
KR20150002879A (ko) | 2006-10-02 | 2015-01-07 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20090175847A1 (en) | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
US20090232801A1 (en) | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
-
2006
- 2006-12-08 RU RU2008128139/10A patent/RU2551782C2/ru active
- 2006-12-08 NO NO20082134A patent/NO345996B1/no unknown
- 2006-12-08 SG SG10201404801YA patent/SG10201404801YA/en unknown
- 2006-12-08 MX MX2008007477A patent/MX2008007477A/es active IP Right Grant
- 2006-12-08 CA CA2632822A patent/CA2632822C/fr active Active
- 2006-12-08 DK DK10196705.7T patent/DK2361638T3/en active
- 2006-12-08 KR KR1020147004753A patent/KR101591206B1/ko active IP Right Grant
- 2006-12-08 AU AU2006326284A patent/AU2006326284B2/en active Active
- 2006-12-08 EP EP14166211.4A patent/EP2808032B1/fr active Active
- 2006-12-08 PT PT101967057T patent/PT2361638E/pt unknown
- 2006-12-08 MY MYPI20081950A patent/MY167887A/en unknown
- 2006-12-08 KR KR1020147030095A patent/KR101591223B1/ko active IP Right Grant
- 2006-12-08 EP EP06829456A patent/EP1959996A2/fr not_active Withdrawn
- 2006-12-08 KR KR1020087017127A patent/KR101505201B1/ko active IP Right Grant
- 2006-12-08 MX MX2012002392A patent/MX358175B/es unknown
- 2006-12-08 RS RS20140144A patent/RS53291B/en unknown
- 2006-12-08 PL PL10196705T patent/PL2361638T3/pl unknown
- 2006-12-08 ES ES10196705.7T patent/ES2454253T3/es active Active
- 2006-12-08 BR BRPI0619748A patent/BRPI0619748B8/pt active IP Right Grant
- 2006-12-08 WO PCT/EP2006/011862 patent/WO2007068412A2/fr active Application Filing
- 2006-12-08 RU RU2015111675/10A patent/RU2015111675A/ru not_active Application Discontinuation
- 2006-12-08 EP EP10196705.7A patent/EP2361638B1/fr active Active
- 2006-12-08 SI SI200631766T patent/SI2361638T1/sl unknown
- 2006-12-08 NZ NZ568012A patent/NZ568012A/en unknown
- 2006-12-08 JP JP2008544834A patent/JP5419131B2/ja active Active
- 2006-12-08 KR KR1020157021618A patent/KR20150098683A/ko not_active Application Discontinuation
- 2006-12-11 US US11/637,213 patent/US7772375B2/en active Active
- 2006-12-12 TW TW103104624A patent/TWI579303B/zh active
- 2006-12-12 AR ARP060105475A patent/AR058326A1/es active IP Right Grant
- 2006-12-12 TW TW095146548A patent/TWI508975B/zh active
-
2008
- 2008-05-01 IL IL191230A patent/IL191230A/en active IP Right Grant
- 2008-05-20 CR CR9995A patent/CR9995A/es not_active Application Discontinuation
- 2008-06-05 ZA ZA2008/04916A patent/ZA200804916B/en unknown
- 2008-06-12 EC EC2008008530A patent/ECSP088530A/es unknown
- 2008-07-11 MA MA31117A patent/MA30163B1/fr unknown
-
2009
- 2009-10-23 US US12/589,570 patent/US20100297132A1/en not_active Abandoned
-
2010
- 2010-02-05 US US12/701,199 patent/US20110070613A1/en not_active Abandoned
- 2010-02-25 JP JP2010039568A patent/JP2010187674A/ja not_active Withdrawn
-
2011
- 2011-01-05 CL CL2011000010A patent/CL2011000010A1/es unknown
- 2011-11-15 PH PH12011502389A patent/PH12011502389A1/en unknown
-
2012
- 2012-02-29 HK HK12102086.7A patent/HK1161141A1/xx unknown
- 2012-05-01 US US13/461,658 patent/US20120244165A1/en not_active Abandoned
- 2012-07-25 US US13/558,256 patent/US20120288896A1/en not_active Abandoned
- 2012-11-08 IL IL222923A patent/IL222923B/en active IP Right Grant
-
2013
- 2013-10-17 JP JP2013216451A patent/JP2014039561A/ja not_active Withdrawn
-
2014
- 2014-03-18 HR HRP20140251TT patent/HRP20140251T1/hr unknown
- 2014-04-04 CY CY20141100259T patent/CY1115014T1/el unknown
- 2014-04-07 HR HRP20140333TT patent/HRP20140333T1/hr unknown
- 2014-08-21 CR CR20140394A patent/CR20140394A/es unknown
-
2015
- 2015-01-19 CR CR20150016A patent/CR20150016A/es unknown
- 2015-02-10 IL IL237169A patent/IL237169A0/en unknown
- 2015-02-10 IL IL237168A patent/IL237168A0/en unknown
- 2015-02-10 IL IL237166A patent/IL237166A0/en unknown
- 2015-02-10 IL IL237167A patent/IL237167A0/en unknown
- 2015-06-02 HK HK15105249.1A patent/HK1204579A1/xx unknown
-
2016
- 2016-01-14 JP JP2016004910A patent/JP6174727B2/ja active Active
-
2017
- 2017-03-31 JP JP2017069675A patent/JP2017153480A/ja not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30163B1 (fr) | Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques | |
MX2009013503A (es) | Anticuerpo monoclonal anti-amiloide-beta. | |
MX2009003468A (es) | Anticuerpo humanizado contra beta amiloide. | |
WO2008060364A3 (fr) | Anticorps | |
MA32300B1 (fr) | Anticorps anti-facteur d humanises et utilisations de ceux-ci | |
MA45655A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA30962B1 (fr) | Anticorps antifacteurs d'humanisés et leurs utilisations. | |
MA30337B1 (fr) | Anticorps | |
MA34120B1 (fr) | Composition pharmaceutique | |
MA33726B1 (fr) | Composes de dioxyde d'iminothiadiazine comme inhibiteurs de bace, compositions et leur utlisation | |
EA200400162A1 (ru) | N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения | |
MA30252B1 (fr) | Vaccin therapeutique | |
WO2002046222A3 (fr) | Compositions et procede de diagnostic de la maladie d'alzheimer | |
AT500379B1 (de) | Tau-proteine | |
EA200700083A1 (ru) | Антитела, направленные против бета-амилоидного пептида, и способы их применения | |
MA31899B1 (fr) | Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant | |
TNSN07401A1 (fr) | Anticorps diriges contre le peptide amyloide-beta, et methodes pour leurs utilisations | |
MX338421B (es) | Anticuerpos fosfoespecificos que reconocen la proteina tau. | |
MX2009012949A (es) | Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos. | |
MA33285B1 (fr) | Anticorps anti-cxcr4 pour le traitement du vih | |
NO20082288L (no) | Monoklonalt anti-ADDL-antistoff og anvendelse derav | |
MA30041B1 (fr) | Immunoglobulines | |
UA102368C2 (ru) | СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА | |
MA31256B1 (fr) | Nouveaux anticorps humains anti-r7v et leurs utilisations | |
MA50675B1 (fr) | Inhibiteurs de la creb binding protein (cbp) |